2020 Form 10-K Financial Statement

#000106299321002958 Filed on March 24, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $38.60M $7.300M $28.32M
YoY Change 36.33% 32.39% 16.09%
Cost Of Revenue $21.22M $4.283M $15.31M
YoY Change 38.56% 39.99% 19.43%
Gross Profit $17.39M $3.017M $13.01M
YoY Change 33.69% 22.91% 12.4%
Gross Profit Margin 45.04% 41.33% 45.93%
Selling, General & Admin $9.286M $2.270M $8.780M
YoY Change 5.77% 12.0% 9.81%
% of Gross Profit 53.4% 75.22% 67.5%
Research & Development $1.523M $427.6K $1.491M
YoY Change 2.12% 20.96% 5.54%
% of Gross Profit 8.76% 14.17% 11.46%
Depreciation & Amortization $832.2K $190.5K $760.2K
YoY Change 9.47% -1.46% 9.29%
% of Gross Profit 4.79% 6.31% 5.84%
Operating Expenses $11.64M $2.874M $11.07M
YoY Change 5.13% 11.29% 9.32%
Operating Profit $5.836M $143.0K $1.981M
YoY Change 194.65% -211.71% 33.21%
Interest Expense -$4.720K -$34.26K -$38.30K
YoY Change -87.68% -172.22% -197.9%
% of Operating Profit -0.08% -23.96% -1.93%
Other Income/Expense, Net $206.0K -$38.30K
YoY Change -637.88% -197.9%
Pretax Income $6.042M $67.20K $1.942M
YoY Change 211.07% -183.44% 27.28%
Income Tax $1.619M $95.19K $566.7K
% Of Pretax Income 26.79% 141.65% 29.18%
Net Earnings $4.424M -$27.99K $1.376M
YoY Change 221.57% 3154.65% 14.95%
Net Earnings / Revenue 11.46% -0.38% 4.86%
Basic Earnings Per Share $0.82 $0.26
Diluted Earnings Per Share $0.74 -$5.196K $0.25
COMMON SHARES
Basic Shares Outstanding 5.390M shares 5.387M shares 5.385M shares
Diluted Shares Outstanding 5.991M shares 5.546M shares

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.025M $2.131M $2.131M
YoY Change 41.96% 20.53% 20.53%
Cash & Equivalents $2.967M $2.073M $2.073M
Short-Term Investments $58.26K $58.24K $58.24K
Other Short-Term Assets $2.914M $1.577M $1.577M
YoY Change 84.85% -8.37% -8.37%
Inventory $9.670M $8.655M $8.655M
Prepaid Expenses $447.5K
Receivables $7.174M $2.956M $2.956M
Other Receivables $2.960K $0.00 $0.00
Total Short-Term Assets $22.79M $15.32M $15.32M
YoY Change 48.75% 47.96% 47.96%
LONG-TERM ASSETS
Property, Plant & Equipment $3.338M $2.431M $2.843M
YoY Change 17.42% 4.9% 22.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $112.4K $26.64K $26.64K
YoY Change 321.92% 4.97% 4.96%
Total Long-Term Assets $3.451M $26.64K $2.870M
YoY Change 20.24% -59.54% 20.41%
TOTAL ASSETS
Total Short-Term Assets $22.79M $15.32M $15.32M
Total Long-Term Assets $3.451M $26.64K $2.870M
Total Assets $26.24M $18.19M $18.19M
YoY Change 44.25% 42.81% 42.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.009M $5.426M $5.426M
YoY Change 47.61% 95.23% 95.23%
Accrued Expenses $207.8K $190.8K $190.8K
YoY Change 8.94%
Deferred Revenue
YoY Change
Short-Term Debt $677.6K $576.5K $876.5K
YoY Change -22.69% -0.97% 50.56%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.55M $7.086M $7.086M
YoY Change 48.87% 106.48% 106.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $318.1K $381.2K $381.2K
YoY Change -16.55% 376.49% 376.49%
Total Long-Term Liabilities $318.1K $381.2K $381.2K
YoY Change -16.55% 376.49% 376.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.55M $7.086M $7.086M
Total Long-Term Liabilities $318.1K $381.2K $381.2K
Total Liabilities $10.87M $7.467M $7.467M
YoY Change 45.53% 102.77% 102.77%
SHAREHOLDERS EQUITY
Retained Earnings $3.038M
YoY Change 82.77%
Common Stock $130.1K
YoY Change 0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.37M $10.72M $10.72M
YoY Change
Total Liabilities & Shareholders Equity $26.24M $18.19M $18.19M
YoY Change 44.25% 42.81% 42.81%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income $4.424M -$27.99K $1.376M
YoY Change 221.57% 3154.65% 14.95%
Depreciation, Depletion And Amortization $832.2K $190.5K $760.2K
YoY Change 9.47% -1.46% 9.29%
Cash From Operating Activities $2.347M -$152.0K $845.6K
YoY Change 177.58% 57.31% -25.75%
INVESTING ACTIVITIES
Capital Expenditures -$1.477M -$257.8K -$874.1K
YoY Change 69.03% -35.91% -10.64%
Acquisitions
YoY Change
Other Investing Activities $25.70K $1.080K $11.08K
YoY Change 131.95% 752.31%
Cash From Investing Activities -$1.452M -$256.7K -$863.0K
YoY Change 68.22% -36.18% -11.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $15.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $11.86K 453.4K $309.3K
YoY Change -96.17% -12.45% 383.37%
NET CHANGE
Cash From Operating Activities $2.347M -152.0K $845.6K
Cash From Investing Activities -$1.452M -256.7K -$863.0K
Cash From Financing Activities $11.86K 453.4K $309.3K
Net Change In Cash $907.3K 44.59K $291.9K
YoY Change 210.8% 135.8% 29.18%
FREE CASH FLOW
Cash From Operating Activities $2.347M -$152.0K $845.6K
Capital Expenditures -$1.477M -$257.8K -$874.1K
Free Cash Flow $3.825M $105.8K $1.720M
YoY Change 122.4% -65.39% -18.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
78700 USD
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2964 USD
CY2020 leat Loan Forgiveness Income Of Paycheck Protection Program
LoanForgivenessIncomeOfPaycheckProtectionProgram
210732 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
196670 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
65942 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 USD
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
80258 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-33655 USD
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
176151 USD
CY2020 leat Stock Issued During Period Value Restricted Stock Awards For Accrued Leave
StockIssuedDuringPeriodValueRestrictedStockAwardsForAccruedLeave
16334 USD
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
210732 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-13156 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1120000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1120000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
120000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
120000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
120000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
120000 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
28000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
28000000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5430374 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5386723 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5430374 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5386723 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
9054065 USD
CY2019 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
41511 USD
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-38300 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6042405 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1942457 USD
CY2019 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
8600 USD
CY2020 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-300000 USD
CY2019 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
300000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
71033 USD
CY2020 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
894178 USD
CY2019 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
362964 USD
CY2020 leat Common Stock Issued For Accrued Leave
CommonStockIssuedForAccruedLeave
16334 USD
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <div style="margin-left:72pt;margin-top:0px;margin-bottom:13px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong>Concentration of Credit Risk - </strong>The Company maintains cash and cash equivalent balances at several financial institutions that are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. </span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span>As of December 31, </span></span></span></span></span></span></span></span></span></span></span></span></span></span>2020, and 2019, the Company's uninsured bank balances totaled $2,710,812 and $1,776,931, respectively.&#160; The Company has not experienced any significant losses on its cash and cash equivalents.</span></span></div> <p style="margin-left:72pt;margin-top:0px;margin-bottom:13px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company's trade receivables are derived from sales to distributors and dealers.&#160; The Company has adopted credit policies and standards intended to accommodate industry growth and inherent risk.&#160; Management believes that credit risks are moderated by the diversity of the Company's end customers and geographic sales areas.&#160; The Company performs ongoing credit evaluations of its customers' financial condition and requires collateral as deemed necessary.&#160; The Company maintains allowances for potential credit losses as needed.</span></span></p> <p style="margin-left:72pt;margin-top:0px;margin-bottom:13px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company has derived, and believes that it will continue to derive, a significant portion of its revenue from a limited number of customers.&#160; For the years ended December 31, 2020 and 2019, the Company's U.S. revenue was concentrated in one customer that accounted for approximately 9% and 11%, respectively, of annual U.S. revenue.&#160;As of December 31, 2020, and 2019, $199,808, or 3% and $35,217, or 1% of the Company's accounts receivable, respectively, were due from this customer.&#160; For the years ended December 31, 2020 and 2019, the Company's international revenue was concentrated in one customer that accounted for approximately 9% and 8%, respectively, of annual international revenue.&#160; As of December 31, 2020, and 2019, $421,976, or 6%, and $0, or 0% of the Company's accounts receivable, respectively, were due from this international customer.&#160; The Company generates revenue both in the United States and internationally.&#160; For the years ended December 31, 2020 and 2019, annual revenues associated with international customers were $24,670,072 and $18,897,942, or 64% and 67% of total revenue, respectively.</span></span></p> </div>
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0088 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.2173 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0278 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0220 pure
CY2020 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1 pure
CY2019 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0143 pure
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0300 pure
CY2020Q4 leat Increase Decrease Amount Of Gross Tax Benefit And Valuation Allowance
IncreaseDecreaseAmountOfGrossTaxBenefitAndValuationAllowance
53900 USD
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
12900000 USD
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
12900000 USD
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
567000 shares
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0295 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0110 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0110 pure
CY2020 us-gaap Deferred Compensation Arrangement With Individual Maximum Contractual Term1
DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
P5Y
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.30
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6000 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
9000 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
250000 shares
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
18000 shares
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.00
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.60
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
62900 USD
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-78700 USD
CY2019 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-108000 USD
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0502 pure
CY2019 leat Amount Paid Included In Measurement Of Lease Liabilities
AmountPaidIncludedInMeasurementOfLeaseLiabilities
223016 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
97096 USD
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
617285 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
231447 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
86867 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
318314 USD
CY2020Q4 leat Imputed Interest Operating
ImputedInterestOperating
32382 USD
CY2020 leat Amount Paid Included In Measurement Of Lease Liabilities
AmountPaidIncludedInMeasurementOfLeaseLiabilities
220992 USD
CY2019Q4 leat Increase Decrease Amount Of Gross Tax Benefit And Valuation Allowance
IncreaseDecreaseAmountOfGrossTaxBenefitAndValuationAllowance
-62900 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
285932 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
411956 USD
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
220992 USD
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
206799 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0487 pure

Files In Submission

Name View Source Status
0001062993-21-002958-index-headers.html Edgar Link pending
0001062993-21-002958-index.html Edgar Link pending
0001062993-21-002958.txt Edgar Link pending
0001062993-21-002958-xbrl.zip Edgar Link pending
exhibit10-10.htm Edgar Link pending
exhibit10-10x4x1.jpg Edgar Link pending
exhibit10-10xu003.jpg Edgar Link pending
exhibit10-10xu004.jpg Edgar Link pending
exhibit10-11.htm Edgar Link pending
exhibit10-11xu035.jpg Edgar Link pending
exhibit10-11xu036.jpg Edgar Link pending
exhibit10-11xu037.jpg Edgar Link pending
exhibit10-11xu038.jpg Edgar Link pending
exhibit10-11xu039.jpg Edgar Link pending
exhibit10-11xu040.jpg Edgar Link pending
exhibit10-11xu041.jpg Edgar Link pending
exhibit10-11xu042.jpg Edgar Link pending
exhibit10-11xu043.jpg Edgar Link pending
exhibit10-11xu044.jpg Edgar Link pending
exhibit10-11xu045.jpg Edgar Link pending
exhibit10-11xu046.jpg Edgar Link pending
exhibit10-11xu047.jpg Edgar Link pending
exhibit10-11xu048.jpg Edgar Link pending
exhibit10-11xu049.jpg Edgar Link pending
exhibit10-11xu050.jpg Edgar Link pending
exhibit10-11xu051.jpg Edgar Link pending
exhibit10-11xu052.jpg Edgar Link pending
exhibit10-11xu053.jpg Edgar Link pending
exhibit10-11xu054.jpg Edgar Link pending
exhibit10-11xu055.jpg Edgar Link pending
exhibit10-11xu056.jpg Edgar Link pending
exhibit10-11xu057.jpg Edgar Link pending
exhibit10-11xu058.jpg Edgar Link pending
exhibit10-11xu059.jpg Edgar Link pending
exhibit10-15.htm Edgar Link pending
exhibit10-15x10x1.jpg Edgar Link pending
exhibit10-15x5x1.jpg Edgar Link pending
exhibit10-15x6x1.jpg Edgar Link pending
exhibit10-15x8x1.jpg Edgar Link pending
exhibit10-15xu001.jpg Edgar Link pending
exhibit10-15xu002.jpg Edgar Link pending
exhibit10-15xu003.jpg Edgar Link pending
exhibit10-15xu004.jpg Edgar Link pending
exhibit10-16.htm Edgar Link pending
exhibit10-16x1x1.jpg Edgar Link pending
exhibit10-16x2x1.jpg Edgar Link pending
exhibit10-16x3x1.jpg Edgar Link pending
exhibit10-16x4x1.jpg Edgar Link pending
exhibit10-16x5x1.jpg Edgar Link pending
exhibit10-16x6x1.jpg Edgar Link pending
exhibit10-16x7x1.jpg Edgar Link pending
exhibit10-16x8x1.jpg Edgar Link pending
exhibit10-16x9x1.jpg Edgar Link pending
exhibit10-16xu001.jpg Edgar Link pending
exhibit10-16xu002.jpg Edgar Link pending
exhibit10-16xu003.jpg Edgar Link pending
exhibit10-16xu004.jpg Edgar Link pending
exhibit10-17.htm Edgar Link pending
exhibit10-17xu010.jpg Edgar Link pending
exhibit10-17xu011.jpg Edgar Link pending
exhibit10-17xu012.jpg Edgar Link pending
exhibit10-17xu013.jpg Edgar Link pending
exhibit10-17xu014.jpg Edgar Link pending
exhibit10-17xu015.jpg Edgar Link pending
exhibit10-17xu016.jpg Edgar Link pending
exhibit10-17xu017.jpg Edgar Link pending
exhibit10-17xu018.jpg Edgar Link pending
exhibit10-18.htm Edgar Link pending
exhibit10-18xu001.jpg Edgar Link pending
exhibit10-5.htm Edgar Link pending
exhibit10-5x10x1.jpg Edgar Link pending
exhibit10-5x11x1.jpg Edgar Link pending
exhibit10-5x12x1.jpg Edgar Link pending
exhibit10-5x13x1.jpg Edgar Link pending
exhibit10-5x14x1.jpg Edgar Link pending
exhibit10-5x15x1.jpg Edgar Link pending
exhibit10-5x16x1.jpg Edgar Link pending
exhibit10-5x17x1.jpg Edgar Link pending
exhibit10-5x18x1.jpg Edgar Link pending
exhibit10-5x19x1.jpg Edgar Link pending
exhibit10-5x1x1.jpg Edgar Link pending
exhibit10-5x20x1.jpg Edgar Link pending
exhibit10-5x2x1.jpg Edgar Link pending
exhibit10-5x3x1.jpg Edgar Link pending
exhibit10-5x4x1.jpg Edgar Link pending
exhibit10-5x5x1.jpg Edgar Link pending
exhibit10-5x6x1.jpg Edgar Link pending
exhibit10-5x7x1.jpg Edgar Link pending
exhibit10-5x8x1.jpg Edgar Link pending
exhibit10-5x9x1.jpg Edgar Link pending
exhibit10-6.htm Edgar Link pending
exhibit10-6x10x1.jpg Edgar Link pending
exhibit10-6x11x1.jpg Edgar Link pending
exhibit10-6x12x1.jpg Edgar Link pending
exhibit10-6x13x1.jpg Edgar Link pending
exhibit10-6x14x1.jpg Edgar Link pending
exhibit10-6x15x1.jpg Edgar Link pending
exhibit10-6x16x1.jpg Edgar Link pending
exhibit10-6x17x1.jpg Edgar Link pending
exhibit10-6x18x1.jpg Edgar Link pending
exhibit10-6x19x1.jpg Edgar Link pending
exhibit10-6x1x1.jpg Edgar Link pending
exhibit10-6x20x1.jpg Edgar Link pending
exhibit10-6x2x1.jpg Edgar Link pending
exhibit10-6x3x1.jpg Edgar Link pending
exhibit10-6x4x1.jpg Edgar Link pending
exhibit10-6x5x1.jpg Edgar Link pending
exhibit10-6x6x1.jpg Edgar Link pending
exhibit10-6x7x1.jpg Edgar Link pending
exhibit10-6x8x1.jpg Edgar Link pending
exhibit10-6x9x1.jpg Edgar Link pending
exhibit10-7.htm Edgar Link pending
exhibit10-7x10x1.jpg Edgar Link pending
exhibit10-7x11x1.jpg Edgar Link pending
exhibit10-7x12x1.jpg Edgar Link pending
exhibit10-7x13x1.jpg Edgar Link pending
exhibit10-7x14x1.jpg Edgar Link pending
exhibit10-7x15x1.jpg Edgar Link pending
exhibit10-7x16x1.jpg Edgar Link pending
exhibit10-7x17x1.jpg Edgar Link pending
exhibit10-7x18x1.jpg Edgar Link pending
exhibit10-7x4x1.jpg Edgar Link pending
exhibit10-7x5x1.jpg Edgar Link pending
exhibit10-7x6x1.jpg Edgar Link pending
exhibit10-7x7x1.jpg Edgar Link pending
exhibit10-7x8x1.jpg Edgar Link pending
exhibit10-7x9x1.jpg Edgar Link pending
exhibit10-7xu001.jpg Edgar Link pending
exhibit10-7xu002.jpg Edgar Link pending
exhibit10-8.htm Edgar Link pending
exhibit10-8x36x1.jpg Edgar Link pending
exhibit10-8x37x1.jpg Edgar Link pending
exhibit10-8x38x1.jpg Edgar Link pending
exhibit10-8x51x1.jpg Edgar Link pending
exhibit10-8xu001.jpg Edgar Link pending
exhibit10-9.htm Edgar Link pending
exhibit10-9x4x1.jpg Edgar Link pending
exhibit10-9xu003.jpg Edgar Link pending
exhibit10-9xu004.jpg Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
exhibit4-16.htm Edgar Link pending
exhibit4-16x1x1.jpg Edgar Link pending
exhibit4-16x2x1.jpg Edgar Link pending
exhibit4-16xu001.jpg Edgar Link pending
exhibit4-16xu002.jpg Edgar Link pending
exhibit4-16xu003.jpg Edgar Link pending
exhibit4-17.htm Edgar Link pending
exhibit4-17x2x1.jpg Edgar Link pending
exhibit4-17xu001.jpg Edgar Link pending
exhibit4-17xu002.jpg Edgar Link pending
exhibit4-17xu003.jpg Edgar Link pending
exhibit4-17xu004.jpg Edgar Link pending
exhibit4-18.htm Edgar Link pending
exhibit4-18xu002.jpg Edgar Link pending
exhibit4-18xu003.jpg Edgar Link pending
exhibit4-18xu004.jpg Edgar Link pending
exhibit4-19.htm Edgar Link pending
exhibit4-19xu001.jpg Edgar Link pending
exhibit4-19xu002.jpg Edgar Link pending
exhibit4-19xu003.jpg Edgar Link pending
exhibit4-19xu004.jpg Edgar Link pending
exhibit4-20.htm Edgar Link pending
exhibit4-20xu001.jpg Edgar Link pending
exhibit4-20xu002.jpg Edgar Link pending
exhibit4-20xu003.jpg Edgar Link pending
exhibit4-20xu004.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
form10kx001.jpg Edgar Link pending
form10kx008.jpg Edgar Link pending
form10kxu001.jpg Edgar Link pending
form10kxu002.jpg Edgar Link pending
leat-20201231.xml Edgar Link completed
leat-20201231.xsd Edgar Link pending
leat-20201231_cal.xml Edgar Link unprocessable
leat-20201231_def.xml Edgar Link unprocessable
leat-20201231_lab.xml Edgar Link unprocessable
leat-20201231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending